Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2018-001680-24-AT
EUCTR2018-001680-24-AT
Active, not recruiting
Phase 1

Combined low-dose everolimus and low-dose tacrolimus after alemtuzumab induction therapy: a randomized prospective trial in lung transplantation - ALiKE

Medical University of Vienna - Abteilung für Thoraxchirurgie0 sites110 target enrollmentJune 27, 2018
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsung TransplantationTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
ung Transplantation
Sponsor
Medical University of Vienna - Abteilung für Thoraxchirurgie
Enrollment
110
Status
Active, not recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 27, 2018
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Medical University of Vienna - Abteilung für Thoraxchirurgie

Eligibility Criteria

Inclusion Criteria

  • •All bilateral lung transplantation
  • •Age \> 18 years
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 110
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 110

Exclusion Criteria

  • •Pediatric patients (age \< 18 years)
  • •Pre\-transplant colonization of Burkholderia or resistant Mycobacterium abscessus
  • •Wound infection at the time of randomization
  • •Inclusion in other studies

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Comparing the use of Everolimus and Tacrolimus reduced dose versus Mycophenolate Sodium and Tacrolimus reduced dose in Liver Transplant patientsiver transplantation immunossupression, hepatic graft rejection and loss, receptor death, immunosuppressive drug myelotoxicity, posttransplant diabetes mellitus, posttransplant dyslipidemia, cytomegalovirus events, hepatic artery thrombosis, bile duct complications, operative wound complications, incisional hernia, postoperative kidney failure, proteinuria, discontinuation of the immunosuppressive regimen.Liver transplantationeverolimustacrolimusmycophenolate sodium.E04.210.650D02.540.505.810D02.540.505.760.500D02.241.081.193.678
RBR-9k66x6Hospital Geral de Fortaleza
Active, not recruiting
Phase 1
Everolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinomaEverolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55%Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-002524-16-SEDept of Oncology. Haukeland University Hospital40
Active, not recruiting
Phase 1
Everolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinomaEverolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55%MedDRA version: 21.0Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-002524-16-DKDept of Oncology. Haukeland University Hospital38
Recruiting
Not Applicable
Management of the combination of tacrolimus with azoles: effect of tacrolimus formulation on drug-drug interaction magnitudeMycoses due to opportunistic pathogensfungal infection in patients with immune deficiencies who would otherwise not be infected10017528
NL-OMON54925niversitair Medisch Centrum Groningen24
Completed
Phase 4
Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal TransplantTransplantation InfectionCytomegalovirus Infections
NCT02084446Ronaldo de Matos Esmeraldo, MD120